(RTTNews.com) - Myriad Genetics Inc. ( MYGN ) announced the results from a large commercial cohort and several clinical studies on development of the adjusted Vectra score that were published in the journal Rheumatology. The key findings are that the adjusted Vectra score significantly outperformed conventional measures of disease activity in predicting radiographic progression (new joint damage) in patients with rheumatoid arthritis or RA.
The results showed that the leptin-adjusted Vectra score was 5.5 times more predictive of radiographic progression, the BMI-adjusted Vectra score was 4.6 times more predictive, and the original Vectra score was four times more predictive when compared to DAS28. Importantly, Vectra also outperformed the other common measures evaluated in this study (Chart 1).
Read the original article on RTTNews (http://www.rttnews.com/2965346/myriad-genetics-publishes-vectra-study-in-journal-rheumatology.aspx)
For comments and feedback: contact email@example.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This StoryMYGN
- Making A List Of The Best Growth Stocks To Buy Now? 1 Up Over 1200% Year-To-Date
- Top EV Stocks To Watch in November 2020; 1 Set To Announce Earnings Today
- Viatris Will Be the New Kid in Generic Drugs. Don't Expect the Stock to Surge, Analyst Says.
- Should Investors Consider These Airline Stocks To Buy Now? 3 Names To Watch